High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice

Abstract

Background:

A recent controlled trial suggested that high-dose biotin supplementation reverses disability progression in patients with progressive multiple sclerosis.

Objective:

To analyze the impact of high-dose biotin in routine clinical practice on disability progression at 12 months.

Methods:

Progressive multiple sclerosis patients who started high-dose biotin at Nantes or Rennes Hospital between 3 June 2015 and 15 September 2017 were included in this prospective study. Disability outcome measures, patient-reported outcome measures, relapses, magnetic resonance imaging (MRI) data, and adverse events were collected at baseline, 6, and 12 months.

Results:

A total of 178 patients were included. At baseline, patients were 52.0 ± 9.4 years old, mean Expanded Disability Status Scale (EDSS) score was 6.1 ± 1.3, mean disease duration was 16.9 ± 9.5 years. At 12 months, 3.8% of the patients had an improved EDSS score. Regarding the other disability scales, scores either remained stable or increased significantly. In total, 47.4% of the patients described stability, 27.6% felt an improvement, and 25% described a worsening. Four patients (2.2%) had a relapse. Of the 74 patients (41.6%) who underwent an MRI, 20 (27.0%) had new T2 lesions, 8 (10.8%) had gadolinium-enhancing lesions. Twenty-five (14%) reported adverse event.

Conclusion:

In this study, high-dose biotin did not seem to be associated with a clear improvement in disability.

Keywords

Biotin multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis progression effectiveness

Get full access to this article

View all access options for this article.

References

Lublin

Reingold

Cohen

, et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 2014; 83(3): 278–286.

Trapp

Stys

PK.

Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8(3): 280–291.

Hartung

H-P

Gonsette

König

, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360(9350): 2018–2025.

Hawker

O’Connor

Freedman

, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460–471.

Montalban

Hauser

Kappos

, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209–220.

Kappos

Bar-Or

Cree

BAC

, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263–1273.

Anagnostouli

Livaniou

Nyalala

, et al. Cerebrospinal fluid levels of biotin in various neurological disorders. Acta Neurol Scand 1999; 99(6): 387–392.

Peyro Saint Paul

Debruyne

Bernard

, et al. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2016; 12(3): 327–344.

McCarty

DiNicolantonio

JJ.

Neuroprotective potential of high-dose biotin. Med Hypotheses 2017; 109: 145–149.

10.

Institute of Medicine (IOM). Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: The National Academies Press, 1998.

11.

Tourbah

Lebrun-Frenay

Edan

, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler 2016; 22(13): 1719–1731.

12.

Sedel

Papeix

Bellanger

, et al. High doses of biotin in chronic progressive multiple sclerosis: A pilot study. Mult Scler Relat Disord 2015; 4(2): 159–169.

13.

Confavreux

Compston

Hommes

, et al. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55(8): 671–676.

14.

Tremlett

Zhu

Petkau

, et al. Natural, innate improvements in multiple sclerosis disability. Mult Scler 2012; 18(10): 1412–1421.

15.

Rice

Filippi

Comi

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54(5): 1145–1155.

16.

Andersen

Elovaara

Färkkilä

, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75(5): 706–710.

17.

Birnbaum

Stulc

High dose biotin as treatment for progressive multiple sclerosis. Mult Scler Relat Disord 2017; 18: 141–143.

18.

Donze

Guyot

Lenne

, et al. EP1620: Effect of MD1003 (high dose pharmaceutical grade biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non-active progressive multiple sclerosis. Mult Scler 2018; 24(S2): 738–980.

19.

Lebrun

Cohen

Mondot

, et al. A case report of solitary sclerosis: This is really multiple sclerosis. Neurol Ther 2017; 6(2): 259–263.

20.

Liegey

Brochet

Moroso

, et al. EP1625: Frequency and description of relapses in a cohort of progressive multiple sclerosis patients treated with high dose biotin. Mult Scler 2018; 24(S2): 738–980.

21.

Granella

Tsantes

Siena

, et al. P750: Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis. Mult Scler 2017; 23(S3): 85–426.

22.

Branger

Derache

Kassis

, et al.P5.348: Relapses during high doses of biotin in progressive multiple sclerosis: A case series. Neurology 2018; 90(Suppl. 15): P5–348.

23.

Pignolet

Ciron

Bucciarelli

, et al. P878: Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin). Mult Scler 2018; 24(S2): 328–529.

24.

Piketty

Prie

Sedel

, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: Validation of a simple method to overcome biotin interference. Clin Chem Lab Med 2017; 55(6): 817–825.

25.

Ardabilygazir

Afshariyamchlou

Mir

, et al. Effect of high-dose biotin on thyroid function tests: Case report and literature review. Cureus 2018; 10(6): e2845.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.17 MB